From Podium To Practice – Breast Cancer ESMO Part 3
In this overview, Dr. Wassim Mchayleh explains the design and significance of VIKTORIA-1, a key study evaluating lasofoxifene-based combinations in ESR1-mutated metastatic breast cancer. He discusses why ESR1 mutations drive endocrine resistance, the rationale for pairing a SERD with CDK4/6 inhibition or targeted agents, and the emerging efficacy signals that have elevated this trial’s clinical relevance.